Search research articles
Contact Us
Filters
Showing results (51-60 of 59) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 59 results.
Molecular Therapy. Advances
|
May 15, 2026
The first oral relaxin receptor RXFP1 agonist for heart failure treatment: Translational studies from non-human primates to humans
Erik Ryberg, Fredrik Bergström, Sebastian Sten, et al.
JACC. Heart Failure
|
May 4, 2023
Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEF
Erik Michaëlsson, Lars H Lund, Camilla Hage, et al.
European Journal of Heart Failure
|
July 20, 2023
Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction
Lars H Lund, Carolyn S P Lam, Patricia E Pizzato, et al.
Plos One
|
July 7, 2012
The chromosome 9p21.3 coronary heart disease risk allele is associated with altered gene expression in normal heart and vascular tissues
Anna P Pilbrow, Lasse Folkersen, John F Pearson, et al.
Journal of Cardiac Failure
|
April 18, 2023
Myeloperoxidase Inhibition in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: SATELLITE Trial Results
Carolyn S P Lam, Lars H Lund, Sanjiv J Shah, et al.
European Journal of Heart Failure
|
May 24, 2024
Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial
Carolyn S P Lam, Lars Køber, Koichiro Kuwahara, et al.
Cardiovascular Research
|
March 4, 2025
A novel long-acting relaxin-2 fusion, AZD3427, improves cardiac performance in non-human primates with cardiac dysfunction
Monika Papworth, Spoorthy Kulkarni, Madeleine Antonsson, et al.
Nature Medicine
|
September 25, 2025
Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial
Michelle L O'Donoghue, David A Morrow, Andrea L Vavere, et al.
Circulation. Cardiovascular Genetics
|
November 16, 2012
Identification of the BCAR1-CFDP1-TMEM170A locus as a determinant of carotid intima-media thickness and coronary artery disease risk
Karl Gertow, Bengt Sennblad, Rona J Strawbridge, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 59) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 59 results.
Molecular Therapy. Advances
|
May 15, 2026
The first oral relaxin receptor RXFP1 agonist for heart failure treatment: Translational studies from non-human primates to humans
Erik Ryberg, Fredrik Bergström, Sebastian Sten, et al.
JACC. Heart Failure
|
May 4, 2023
Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEF
Erik Michaëlsson, Lars H Lund, Camilla Hage, et al.
European Journal of Heart Failure
|
July 20, 2023
Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction
Lars H Lund, Carolyn S P Lam, Patricia E Pizzato, et al.
Plos One
|
July 7, 2012
The chromosome 9p21.3 coronary heart disease risk allele is associated with altered gene expression in normal heart and vascular tissues
Anna P Pilbrow, Lasse Folkersen, John F Pearson, et al.
Journal of Cardiac Failure
|
April 18, 2023
Myeloperoxidase Inhibition in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: SATELLITE Trial Results
Carolyn S P Lam, Lars H Lund, Sanjiv J Shah, et al.
European Journal of Heart Failure
|
May 24, 2024
Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial
Carolyn S P Lam, Lars Køber, Koichiro Kuwahara, et al.
Cardiovascular Research
|
March 4, 2025
A novel long-acting relaxin-2 fusion, AZD3427, improves cardiac performance in non-human primates with cardiac dysfunction
Monika Papworth, Spoorthy Kulkarni, Madeleine Antonsson, et al.
Nature Medicine
|
September 25, 2025
Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial
Michelle L O'Donoghue, David A Morrow, Andrea L Vavere, et al.
Circulation. Cardiovascular Genetics
|
November 16, 2012
Identification of the BCAR1-CFDP1-TMEM170A locus as a determinant of carotid intima-media thickness and coronary artery disease risk
Karl Gertow, Bengt Sennblad, Rona J Strawbridge, et al.
Page
of 6